Oral Session 1-13B Conditioning Regimens (2)

[OS1-13B-2] The impact of reduced dose of MMF on MAC based HLA-haploidentical PBSCT using PTCy

Junichi Sugita¹, Koji Nagafuji², Kazuteru Ohashi³, Miho Nara⁴, Nobuhiko Uoshima⁵, Shinya Kimura⁶, Keitaro Matsuo⁷, Koichi Akashi⁸, Shuichi Taniguchi⁹, Mine Harada¹⁰, Takanori Teshima¹ (1.Hematology, Hokkaido University Hospital, Sapporo, Japan, 2.Hematology and oncology, Kurume University Hospital, Kurume, Japan, 3.Hematology, Komagome Hospital, Tokyo, Japan, 4.Hematology, Akita University Hospital, Akita, Japan, 5.Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan, 6.Hematology and Oncology, Saga University Hospital, Saga, Japan, 7.Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan, 8.Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan, 9.Hematology, Toranomon Hospital, Tokyo, Japan, 10.Karatsu Higashimatsuura Medical Center, Karatsu, Japan)